Compugen Reports Fourth Quarter and Full Year 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
March 4, 2025 10:26 AM ESTRodman & Renshaw analyst Tony Blair reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).
The analyst comments "This morning, before the market opened, Compugen Ltd. (CGEN; Buy) released its business updates for 4Q24. The company reported an ending cash balance of $103.3 million for the quarter, which is expected to provide funding into 2027. CGEN remains on track to initiate a randomized adaptive platform trial in 2Q25 to... More
